Bitter melon juice targets molecular mechanisms underlying gemcitabine resistance in pancreatic cancer cells

Somasagara,Ranganatha R.; Deep,Gagan; Shrotriya,Sangeeta; Patel,Manisha; Agarwal,Chapla; Agarwal,Rajesh

doi:10.3892/ijo.2015.2885

Bitter melon juice targets molecular mechanisms underlying gemcitabine resistance in pancreatic cancer cells

Authors:
- Ranganatha R. Somasagara
- Gagan Deep
- Sangeeta Shrotriya
- Manisha Patel
- Chapla Agarwal
- Rajesh Agarwal
View Affiliations

Affiliations: Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
Published online on: February 9, 2015 https://doi.org/10.3892/ijo.2015.2885
Pages: 1849-1857

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pancreatic cancer (PanC) is one of the most lethal malignancies, and resistance towards gemcitabine, the front‑line chemotherapy, is the main cause for dismal rate of survival in PanC patients; overcoming this resistance remains a major challenge to treat this deadly malignancy. Whereas several molecular mechanisms are known for gemcitabine resistance in PanC cells, altered metabolism and bioenergetics are not yet studied. Here, we compared metabolic and bioenergetic functions between gemcitabine‑resistant (GR) and gemcitabine‑sensitive (GS) PanC cells and underlying molecular mechanisms, together with efficacy of a natural agent bitter melon juice (BMJ). GR PanC cells showed distinct morphological features including spindle‑shaped morphology and a decrease in E‑cadherin expression. GR cells also showed higher ATP production with an increase in oxygen consumption rate (OCR) and extracellular acidification rate (ECAR). Molecular studies showed higher expression of glucose transporters (GLUT1 and 4) suggesting an increase in glucose uptake by GR cells. Importantly, GR cells showed a significant increase in Akt and ERK1/2 phosphorylation and their inhibition decreased cell viability, suggesting their role in survival and drug resistance of these cells. Recently, we reported strong efficacy of BMJ against a panel of GS cells in culture and nude mice, which we expanded here and found that BMJ was also effective in decreasing both Akt and ERK1/2 phosphorylation and viability of GR PanC cells. Overall, we have identified novel mechanisms of gemcitabine resistance in PanC cells which are targeted by BMJ. Considering the short survival in PanC patients, our findings could have high translational potential in controlling this deadly malignancy.

View Figures

View References

1	Guillermet-Guibert J, Davenne L, Pchejetski D, Saint-Laurent N, Brizuela L, Guilbeau-Frugier C, Delisle MB, Cuvillier O, Susini C and Bousquet C: Targeting the sphingolipid metabolism to defeat pancreatic cancer cell resistance to the chemotherapeutic gemcitabine drug. Mol Cancer Ther. 8:809–820. 2009. View Article : Google Scholar : PubMed/NCBI
2	Huanwen W, Zhiyong L, Xiaohua S, Xinyu R, Kai W and Tonghua L: Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines. Mol Cancer. 8:1252009. View Article : Google Scholar : PubMed/NCBI
3	Di Marco M, Di Cicilia R, Macchini M, Nobili E, Vecchiarelli S, Brandi G and Biasco G: Metastatic pancreatic cancer: Is gemcitabine still the best standard treatment? (Review). Oncol Rep. 23:1183–1192. 2010. View Article : Google Scholar : PubMed/NCBI
4	Kagawa S, Takano S, Yoshitomi H, et al: Akt/mTOR signaling pathway is crucial for gemcitabine resistance induced by Annexin II in pancreatic cancer cells. J Surg Res. 178:758–767. 2012. View Article : Google Scholar : PubMed/NCBI
5	Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C and Gottesman MM: Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 5:219–234. 2006. View Article : Google Scholar : PubMed/NCBI
6	Fanciulli M, Bruno T, Giovannelli A, Gentile FP, Di Padova M, Rubiu O and Floridi A: Energy metabolism of human LoVo colon carcinoma cells: correlation to drug resistance and influence of lonidamine. Clin Cancer Res. 6:1590–1597. 2000.PubMed/NCBI
7	Zhou M, Zhao Y, Ding Y, et al: Warburg effect in chemosensitivity: Targeting lactate dehydrogenase-A re-sensitizes taxol-resistant cancer cells to taxol. Mol Cancer. 9:332010. View Article : Google Scholar : PubMed/NCBI
8	Vivanco I and Sawyers CL: The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer. 2:489–501. 2002. View Article : Google Scholar : PubMed/NCBI
9	Tokunaga E, Oki E, Egashira A, Sadanaga N, Morita M, Kakeji Y and Maehara Y: Deregulation of the Akt pathway in human cancer. Curr Cancer Drug Targets. 8:27–36. 2008. View Article : Google Scholar : PubMed/NCBI
10	McCubrey JA, Steelman LS, Chappell WH, et al: Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 1773:1263–1284. 2007. View Article : Google Scholar
11	Elstrom RL, Bauer DE, Buzzai M, et al: Akt stimulates aerobic glycolysis in cancer cells. Cancer Res. 64:3892–3899. 2004. View Article : Google Scholar : PubMed/NCBI
12	Gottlob K, Majewski N, Kennedy S, Kandel E, Robey RB and Hay N: Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev. 15:1406–1418. 2001. View Article : Google Scholar : PubMed/NCBI
13	Plas DR, Talapatra S, Edinger AL, Rathmell JC and Thompson CB: Akt and Bcl-xL promote growth factor-independent survival through distinct effects on mitochondrial physiology. J Biol Chem. 276:12041–12048. 2001. View Article : Google Scholar : PubMed/NCBI
14	Majewski N, Nogueira V, Bhaskar P, Coy PE, Skeen JE, Gottlob K, Chandel NS, Thompson CB, Robey RB and Hay N: Hexokinase-mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak. Mol Cell. 16:819–830. 2004. View Article : Google Scholar : PubMed/NCBI
15	Huang WC and Hung MC: Induction of Akt activity by chemotherapy confers acquired resistance. J Formos Med Assoc. 108:180–194. 2009. View Article : Google Scholar : PubMed/NCBI
16	Duxbury MS, Ito H, Zinner MJ, Ashley SW and Whang EE: siRNA directed against c-Src enhances pancreatic adenocarcinoma cell gemcitabine chemosensitivity. J Am Coll Surg. 198:953–959. 2004. View Article : Google Scholar : PubMed/NCBI
17	Yibchok-anun S, Adisakwattana S, Yao CY, Sangvanich P, Roengsumran S and Hsu WH: Slow acting protein extract from fruit pulp of Momordica charantia with insulin secretagogue and insulinomimetic activities. Biol Pharm Bull. 29:1126–1131. 2006. View Article : Google Scholar : PubMed/NCBI
18	Ganguly C, De S and Das S: Prevention of carcinogen-induced mouse skin papilloma by whole fruit aqueous extract of Momordica charantia. Eur J Cancer Prev. 9:283–288. 2000. View Article : Google Scholar : PubMed/NCBI
19	Claflin AJ, Vesely DL, Hudson JL, Bagwell CB, Lehotay DC, Lo TM, Fletcher MA, Block NL and Levey GS: Inhibition of growth and guanylate cyclase activity of an undifferentiated prostate adenocarcinoma by an extract of the balsam pear (Momordica charantia abbreviata). Proc Natl Acad Sci USA. 75:989–993. 1978. View Article : Google Scholar : PubMed/NCBI
20	Nagasawa H, Watanabe K and Inatomi H: Effects of bitter melon (Momordica charantia L.) or ginger rhizome (Zingiber offifinale rosc) on spontaneous mammary tumorigenesis in SHN mice. Am J Chin Med. 30:195–205. 2002. View Article : Google Scholar : PubMed/NCBI
21	Singh A, Singh SP and Bamezai R: Momordica charantia (Bitter Gourd) peel, pulp, seed and whole fruit extract inhibits mouse skin papillomagenesis. Toxicol Lett. 94:37–46. 1998. View Article : Google Scholar : PubMed/NCBI
22	Weng JR, Bai LY, Chiu CF, Hu JL, Chiu SJ and Wu CY: Cucurbitane triterpenoid from Momordica charantia induces apoptosis and autophagy in breast cancer cells, in part, through peroxisome proliferator-activated receptor γ activation. Evid Based Complement Alternat Med. 2013:9356752013. View Article : Google Scholar
23	Kwatra D, Subramaniam D, Ramamoorthy P, Standing D, Moran E, Velayutham R, Mitra A, Umar S and Anant S: Methanolic extracts of bitter melon inhibit colon cancer stem cells by affecting energy homeostasis and autophagy. Evid Based Complement Alternat Med. 2013:7028692013. View Article : Google Scholar : PubMed/NCBI
24	Hsiao PC, Liaw CC, Hwang SY, Cheng HL, Zhang LJ, Shen CC, Hsu FL and Kuo YH: Antiproliferative and hypoglycemic cucurbitane-type glycosides from the fruits of Momordica charantia. J Agric Food Chem. 61:2979–2986. 2013. View Article : Google Scholar : PubMed/NCBI
25	Limtrakul P, Khantamat O and Pintha K: Inhibition of P-glycoprotein activity and reversal of cancer multidrug resistance by Momordica charantia extract. Cancer Chemother Pharmacol. 54:525–530. 2004. View Article : Google Scholar : PubMed/NCBI
26	Kaur M, Deep G, Jain AK, Raina K, Agarwal C, Wempe MF and Agarwal R: Bitter melon juice activates cellular energy sensor AMP-activated protein kinase causing apoptotic death of human pancreatic carcinoma cells. Carcinogenesis. 34:1585–1592. 2013. View Article : Google Scholar : PubMed/NCBI
27	Agarwal C, Tyagi A, Kaur M and Agarwal R: Silibinin inhibits constitutive activation of Stat3, and causes caspase activation and apoptotic death of human prostate carcinoma DU145 cells. Carcinogenesis. 28:1463–1470. 2007. View Article : Google Scholar : PubMed/NCBI
28	Wu M, Neilson A, Swift AL, et al: Multiparameter metabolic analysis reveals a close link between attenuated mitochondrial bioenergetic function and enhanced glycolysis dependency in human tumor cells. Am J Physiol Cell Physiol. 292:C125–C136. 2007. View Article : Google Scholar
29	Brand MD and Nicholls DG: Assessing mitochondrial dysfunction in cells. Biochem J. 435:297–312. 2011. View Article : Google Scholar : PubMed/NCBI
30	Potter VR and Reif AE: Inhibition of an electron transport component by antimycin A. J Biol Chem. 194:287–297. 1952.PubMed/NCBI
31	Kasuya K, Tsuchida A, Nagakawa Y, Suzuki M, Abe Y, Itoi T, Serizawa H, Nagao T, Shimazu M and Aoki T: Hypoxia-inducible factor-1α expression and gemcitabine chemotherapy for pancreatic cancer. Oncol Rep. 26:1399–1406. 2011.PubMed/NCBI
32	Zhao Y, Butler EB and Tan M: Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis. 4:e5322013. View Article : Google Scholar : PubMed/NCBI
33	Gao T, Furnari F and Newton AC: PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell. 18:13–24. 2005. View Article : Google Scholar : PubMed/NCBI
34	Gao AM, Ke ZP, Shi F, Sun GC and Chen H: Chrysin enhances sensitivity of BEL-7402/ADM cells to doxorubicin by suppressing PI3K/Akt/Nrf2 and ERK/Nrf2 pathway. Chem Biol Interact. 206:100–108. 2013. View Article : Google Scholar : PubMed/NCBI
35	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
36	Tang D, Okada H, Ruland J, Liu L, Stambolic V, Mak TW and Ingram AJ: Akt is activated in response to an apoptotic signal. J Biol Chem. 276:30461–30466. 2001. View Article : Google Scholar : PubMed/NCBI
37	Jeong EK, Lee SY, Jeon HM, Ju MK, Kim CH and Kang HS: Role of extracellular signal-regulated kinase (ERK)1/2 in multicellular resistance to docetaxel in MCF-7 cells. Int J Oncol. 37:655–661. 2010.PubMed/NCBI
38	Mirmohammadsadegh A, Mota R, Gustrau A, Hassan M, Nambiar S, Marini A, Bojar H, Tannapfel A and Hengge UR: ERK1/2 is highly phosphorylated in melanoma metastases and protects melanoma cells from cisplatin-mediated apoptosis. J Invest Dermatol. 127:2207–2215. 2007. View Article : Google Scholar : PubMed/NCBI
39	Song J, Qu Z, Guo X, Zhao Q, Zhao X, Gao L, Sun K, Shen F, Wu M and Wei L: Hypoxia-induced autophagy contributes to the chemoresistance of hepatocellular carcinoma cells. Autophagy. 5:1131–1144. 2009. View Article : Google Scholar : PubMed/NCBI
40	Sui X, Chen R, Wang Z, et al: Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. Cell Death Dis. 4:e8382013. View Article : Google Scholar : PubMed/NCBI
41	Carew JS, Nawrocki ST, Kahue CN, Zhang H, Yang C, Chung L, Houghton JA, Huang P, Giles FJ and Cleveland JL: Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. Blood. 110:313–322. 2007. View Article : Google Scholar : PubMed/NCBI
42	Yang ZJ, Chee CE, Huang S and Sinicrope FA: The role of autophagy in cancer: therapeutic implications. Mol Cancer Ther. 10:1533–1541. 2011. View Article : Google Scholar : PubMed/NCBI